BeGeV: Difference between revisions
From OncoWiki
Jump to navigationJump to search
(Created page with "== Hodgkin disease == salvage regimen in relapsed Hodgkin's lymphoma == Regimen == phase II study * Gemcitabine 800 mg/m2 on days 1 and 4 * Vinorelbine 20 mg/m2 on day 1, *...") |
(No difference)
|
Latest revision as of 13:06, 14 June 2017
Hodgkin disease
salvage regimen in relapsed Hodgkin's lymphoma
Regimen
phase II study
- Gemcitabine 800 mg/m2 on days 1 and 4
- Vinorelbine 20 mg/m2 on day 1,
- Bendamustine 90 mg/m2 on days 2 and 3
- Prednisolone 100 mg per day was administered on days 1 to 4
Patients received four cycles of the BeGEV regimen administered every 21 days. Growth factor support with granulocyte colony-stimulating factor (G-CSF) was administered at each cycle. Patients received Pneumocystis pneumonia prophylaxis and antiemetics in accordance with institutional guidelines.